PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA

• C. Soussain,
• C. Grommes,
• R. Ward,
• C. Peterson,
• M. Cravets,
• A. Mathias,
• J. Sosa,
• B. Kirby,
• Z. Ding,
• I. Yusuf,
• M. Rose,
• M. Steinberg,
• H. Tun

Affiliations

C. Soussain

1 Institut Curie, Saint-Cloud, France

C. Grommes

2 Memorial Sloan Kettering Cancer Center, New York, NY

R. Ward

3 Gossamer Bio, Inc., San Diego, CA

C. Peterson

3 Gossamer Bio, Inc., San Diego, CA

M. Cravets

3 Gossamer Bio, Inc., San Diego, CA

A. Mathias

3 Gossamer Bio, Inc., San Diego, CA

J. Sosa

3 Gossamer Bio, Inc., San Diego, CA

B. Kirby

3 Gossamer Bio, Inc., San Diego, CA

Z. Ding

3 Gossamer Bio, Inc., San Diego, CA

I. Yusuf

3 Gossamer Bio, Inc., San Diego, CA

M. Rose

3 Gossamer Bio, Inc., San Diego, CA

M. Steinberg

3 Gossamer Bio, Inc., San Diego, CA

H. Tun

4 Mayo Clinic, Jacksonville, FL, United States of America